Agenus reported its 2025 financial results, highlighting significant progress in clinical development, patient access, and manufacturing readiness for its BOT+BAL immunotherapy combination:
“Agenus reported 2025 financial results and key progress across clinical development, patient access, and manufacturing readiness for the BOT+BAL immunotherapy combination.
Key highlights:
- Phase 3 BATTMAN trial underway in refractory MSS metastatic colorectal cancer (mCRC)
- • 42% two-year OS and ~21-month median OS observed in heavily pretreated MSS mCRC patients
- • Early access programs expanding globally, with 200+ physician inquiries across 30+ countries
- • $4.2M in initial revenue recognized from access programs
- • Zydus collaboration strengthens manufacturing capacity and balance sheet
Read the full release.
Barak Kassar, Co-Founder of BKW Partners, also shared his perspective, highlighting these developments and their broader impact:
“Nice. Agenus is reporting good news in today’s earnings. What a great group of people for BKW Partners/BKW Health to be working with as they convert “cold” (immune-resistant) tumors into “hot” (immune-active) ones making immunotherapy more widely effective. I like this pic of a lab freezer I took while visiting their UK facility a couple of years ago.
- Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized
- Colorectal cancer leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month median overall survival in heavily pretreated microsatellite stable (MSS) metastatic CRC (mCRC) patients
- Phase 3 registrational trial underway: First global next-generation CTLA-4/PD-1 combination registrational trial in refractory MSS mCRC
- France expands reimbursed access: Metastatic ovarian cancer and sarcoma added alongside MSS mCRC
- Zydus Group collaboration strengthens balance sheet and manufacturing capacity: Strategic capital and dedicated U.S. biologics production secured to support BOT+BAL development for commercialization.”
You can also read other articles from Agenus on OncoDaily.